Stock Analiz

Akebia Therapeutics, Inc. AKBA

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$0.47Market cap $132M
Open the interactive analysis →

Akebia Therapeutics, Inc. (AKBA) is a healthcare company listed in the US with a market value of about $132M. In the twelve months to September 30, 2026 it had revenue of $197M and net income of -$45M, a net margin of -22.6%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is track record (0/5).

Key numbers: a price to free cash flow of 9.5, 5-year revenue growth of -4% a year, a 5-year average ROIC of -111%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 81% below the current price.

About Akebia Therapeutics

Akebia Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $181M in 2017 to $236M in 2025, growth of about 3.4% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 41% over three years (dilution for shareholders). It spends 26% of revenue on research and development.

Score: 1.4 / 5

Value1/5
Future growth3/5
Track record0/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • P/FCF below 20
  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF9.5
P/S0.7
P/B6.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield10.5%
Shareholder yield0.0%
Intrinsic value vs. price−81%

Growth and quality

Revenue growth (1 yr)47.5%
Revenue growth (5 yrs, per year)-4.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-47.5%
ROIC (5-yr avg.)-111.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$197M$236M$160M$195M$292M$212M$295M$335M$208M$181M
Net income-$45M-$5M-$69M-$52M-$94M-$282M-$385M-$280M-$144M-$74M
Free cash flow$14M$68M-$41M-$23M-$73M-$253M-$111M-$264M-$99M-$58M
EPS (diluted)$-0.16$-0.02$-0.33$-0.28$-0.52$-1.70$-2.78$-2.36$-2.47$-1.69
Net margin-22.6%-2.3%-43.3%-26.7%-32.2%-133.2%-130.6%-83.5%-69.1%-40.6%
ROIC—22.0%—-263.8%-76.9%-125.7%-101.9%-55.8%-22.9%-49.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Akebia Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 81% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Akebia Therapeutics pay a dividend?

Not currently.

Is Akebia Therapeutics a good stock to buy?

We do not give buy or sell advice. Akebia Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.